General characteristic of study population n Mean [+ or -] SD Gender (male/female) 263 128/135 Glycocerebrosidase (nmol/mL/h) 263 1.87[+ or -]1.44 [alpha] glycosidase (nmol/mL/h) 198 2.62[+ or -]1.34 [alpha] galactosidase
(nmol/mL/h) 213 6.03[+ or -]3.67 Sphingomyelinase (nmol/mL/h) 181 10.32[+ or -]7.81 Galactocerebrosidase (nmol/mL/h) 170 1.33[+ or -]0.89 Hemoglobin (g/dL) 263 11.94[+ or -]1.89 Hematocrite (%) 263 36.71[+ or -]5.43 Total leucocyte/[mm.sup.3] 263 8.916[+ or -]3.748 Neutrophil number/[mm.sup.3] 263 3.861[+ or -]2.261 Lymphocyte number/[mm.sup.3] 263 3.846[+ or -]2.482 Thrombocyte number/[mm.sup.3] 263 291.839[+ or -]122.747 SD: Standard deviation
Eng, "Alpha Galactosidase
a deficiency: fabry disease," in The Metabolic And Molecular Basis of Inherited Disease, C.
Husain, "Calcium alginate entrapped preparations of Aspergillus oryzae [beta] galactosidase
: its stability and applications in the hydrolysis of lactose," International Journal of Biological Macromolecules, vol.
activity was determined using chromogenic substrate o-nitrophenyl- b- galactoside (ONPG) and the released amount of the product o- nitrophenol was determined.
amazonensis [beta]- Episomal Promastigotes 39 Galactosidase
The results demonstrated that the probiotics grow better in sonicated yogurt than in unsonicated yogurt, indicating the availability of more nutrients for the probiotics due to a greater availability of galactosidase
. The viability of probiotics increased by 2 log cycles in sonicated yogurt, compared to just one-half log cycle in the unsonicated yogurt.
A 2.3 kb EcoRI-NheI DNA fragment was gel purified and ligated into the polycloning site of the expression vector, pJY505, which is upstream and in frame of the lacZ gene that encodes [beta] galactosidase
. This Punch pO.380 promoter::lacZ vector can be injected into Drosophila embryos, and tissue specific expression of this construct can be detected by staining tissues with the [beta] galactosidase
chromogenic substrate, X Gal.
Avocado [alpha]- galactosidase
and [beta]-galactosidase have previously been shown to solubilize pectin, an important structural component of primary cell walls in fruit tissue.
This solution is derived from Aspergillus niger and contains 650 galactosidase
units of enzymatic activity per gram.
It was for the first time in 1898 that skin lesions of Fabry's was reported by Johann Fabry and William Anderson from Germany and England respectively.5,6 In 1947, Pompen et al further described it to be a generalized storage disorder because of abnormal vacuoles found in virtually all cells of the affected individuals.7 In1963, the material that accumulates in the cells of Fabry's patients was identified as neutral glycosphingolipid.8 In 1967, Brady et al found that the disease is caused by deficiency of an enzyme galactosidase
, required for glycosphingolipid metabolism.9 In 1970, Kint reported the anomeric configuration of terminal galactoside linkage to be alpha.10 In the late 1980, the full length cDNA was isolated and the entire gene sequence of a-galactosidase was derermined.11,12
where [Y.sub.[beta]-galactosidase] is the predicted activity of [beta]- galactosidase
activity U/g beads, [X.sub.1] and [X.sub.2] are the independent variables corresponding to the loading time and amount of loading units, respectively, [[beta].sub.0] is the intercept, [[beta].sub.1] and [[beta].sub.2], are linear coefficients, [[beta].sub.11] and [[beta].sub.22], are quadratic coefficients, and [[beta].sub.12] is cross product coefficients.
Large Scale Biology Corporation (Vacaville, CA) has patented galactosidase
truncated at the carboxy terminus and the production of enzymatically active recombinant human and animal lysosomal enzymes involving construction and expression of recombinant expression constructs comprising coding sequences of human or animal lysosomal enzymes in a plant expression system.